The complex interplay between gut microbes can have a sizable impact on our overall health. One key dynamic within the gut microbiome is the competition for nutrients such as mucin, carbohydrates (sugars), dietary fibers (prebiotics) and amino acids which are vital for their growth. This rivalry plays a crucial role in defining which microbes thrive and their roles, significantly impacting our overall health. We explore IgY’s mechanisms of action against pathogens and how it can play a role in maintaining gut immunity and homeostasis.

Pathogens in the gut are harmful microorganisms, including bacteria, viruses, fungi, and parasites, that have the potential to disrupt the normal function of the gut microbiome.

Pathogens can enter the gut through various means, including contaminated food or water, person-to-person contact, contact with infected animals, and through gas exchange with the environment. Poor hygiene practices, such as inadequate handwashing, can also encourage the transmission of gut pathogens.

Once ingested, these harmful microorganisms can colonize the gastrointestinal tract, leading to a range of digestive issues, malabsorption depriving the body of essential nutrients, and cause diseases and infections, all which can potentially impact overall health. Furthermore, certain pathogens can produce toxins that directly harm the gut barrier, gut immunity and disrupt normal gut functions.

Competition for Nutrients in the Gut

The gut presents a fiercely competitive habitat for bacteria, characterized by its warmth, constant presence of moisture, and an uninterrupted supply of food. When harmful pathogens in the gut compete for nutrients to survive and proliferate, it can be described as a battle of survival against the host’s beneficial microbes.  If pathogens outcompete the good microbes (commensals) in the gut for nutrients, physical space, or gases this can cause a disruption in the balance of gut bacteria, or dysbiosis due to overgrowth of harmful bacteria.

Pathogens can more easily colonize an intestine with a low diversity gut microbiota that does not utilize all the available nutrients. This can sometimes occur following antibiotic treatment or other pharmaceutical interventions ⁽¹⁾. Antibiotic treatment can significantly disrupt the gut microbiome, eliminating not only harmful bacteria but also beneficial ones, and potentially increasing susceptibility to infections and compromising the immune system’s effectiveness. Antibiotics can clear up new niches for pathogenic bacteria to colonize. Some research also greatly suggests that antibiotics also can cause fungal overgrowths for the very same reasons.

Moreover, studies have also shown some pathogens have evolved mechanisms to hijack nutrient supply. This resulting in dysbiosis, which is a long-term perturbation in the composition of the microbial species in the gut, in the loss of microbiome diversity further impairing commensals ability to protect against harmful pathogens and also enhancing the pathogen’s ability to cause health issues.

This dysbiosis is known to be associated with numerous chronic health problems, such as inflammatory bowel disease, obesity, diabetes, mental health conditions and generally speaking, most chronic inflammatory conditions.

Introduction of new pathogenic strains can also trigger the immune system, leading to inflammation and damage to the gut lining, inflammatory bowel disease, obesity, and potentially increasing the risk of systemic diseases.

IgY in the Gut Environment

One novel strategy to balance gut dysbiosis, by way of pathogen removal, is with the use of IgY antibodies. IgY antibodies, derived from the hen eggs, can effectively target, and neutralize pathogens in the gut. IgY-based therapy does not cause disruption of the host flora, like antibiotics, because it only selectively targets disease-causing pathogens ⁽²⁾. A unique aspect of IgY antibodies is their versatility in targeting various survival mechanisms of pathogenic bacteria, such as neutralizing bacterial toxins and blocking colonization of the gut’s mucosa. For example, IgY can target different factors important for the survival of bacteria such as enzymes, toxins, colonization factors, motility molecules, and mucosal receptors allowing for effective suppression of pathogenic bacteria while also minimizing disturbances to beneficial gut flora.

Muno-IgY as a Pathogen Management Tool

Our nutraceutical ingredient, Muno-IgY contains numerous pathogenic targets such as for Escherichia coli (E. coli), Salmonella enterica (S. enterica), and Pseudomonas aeruginosa (P. aeruginosa), a common bacterium that can cause infections in the body, especially in individuals with weakened immune systems. Strains of S. enterica and E. coli are known to cause “stomach flu” which is a common food-borne illness that can seriously harm very old and young people alike. Helicobacter pylori (H. pylori) is another such infection, which primarily impacts the stomach, which if left untreated can result in peptic ulcers and ultimately, cancer. P. aeruginosa is also known for its resistance to antibiotics, making infections difficult to treat and a serious concern in hospital settings.

Muno-IgY is a 100% natural set of broad-spectrum polyclonal antibodies extracted from hen egg yolks at high volumes and high purity and is ideal for nutraceutical applications in a powder format.

1. Horrocks V, King OG, Yip AYG, Marques IM, McDonald JAK. Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization. Microbiology (Reading). 2023;169(8):001377. doi:10.1099/mic.0.001377
2. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695-703. doi:10.1038/nrmicro974